| Literature DB >> 28954415 |
Dan Cheng1, Ghualm Murtaza2,3,4, Suya Ma5, Lingling Li6, Xinjie Li7, Fangze Tian8, Junchao Zheng9, Yi Lu10.
Abstract
Purpose: Depression is a sickening psychiatric condition that is prevalent worldwide. To manage depression, the underlying modes of antidepressant effect of herbals are important to be explored for the development of natural drugs. Tiansi Liquid is a traditional Chinese medicine (TCM) that is prescribed for the management of depression, however its underlying mechanism of action is still uncertain. The purpose of this study was to systematically investigate the pharmacological mode of action of a herbal formula used in TCM for the treatment of depression.Entities:
Keywords: Cytoscape; STITCH; Tiansi Liquid; biological effects; depression; mechanism of action; molecular targets
Mesh:
Substances:
Year: 2017 PMID: 28954415 PMCID: PMC6151506 DOI: 10.3390/molecules22101614
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Factors contributing to the pathophysiology of depression.
Figure 2Flow chart presentation of systematic procedure utilized in this study.
Figure 3Action view of the protein network of Tiansi Liquid targets. Action type is represented by colored edges, as described here: activation () inhibition (), binding (), catalysis (-), phenotype (), posttranslational modification (), reaction () and transcriptional regulation (). Action effects are shown by following signs: Positive (), negative () and unspecified (). Note: MIF—macrophage migration inhibitory factor; MAPK1—mitogen-activated protein kinase 1; HMOX1—heme oxygenase (decycling) 1; PON2—paraoxonase 2; CCND1—cyclin D1; CSN1S1—casein alpha s1; APOE—apolipoprotein E; NR1H2—nuclear receptor subfamily 1, group H, member 2; PPARA—peroxisome proliferator-activated receptor alpha; UCP1—uncoupling protein 1; STK17B—serine/threonine kinase 17b; AKT1—v-akt murine thymoma viral oncogene homolog 1; EGFR—epidermal growth factor receptor; NOS3—nitric oxide synthase 3; ACHE—Acetylcholinesterase; IL8—interleukin 8; CASP3—caspase 3; ADIPOQ—adiponectin, C1Q; NOS2—nitric oxide synthase 2; PRKCD—protein kinase C; NR1I2—nuclear receptor subfamily 1, group I, member 2; FDPS—farnesyl diphosphate synthase; MAPK8—mitogen-activated protein kinase 8; COMT—catechol-O-methyltransferase; NPY1R—neuropeptide Y receptor Y1; PTGS2—prostaglandin-endoperoxide synthase 2; MCL1—myeloid cell leukemia sequence 1 (BCL2 -related); DHCR24—24-dehydrocholesterol reductase; RUNX2—runt-related transcription factor 2; ALOX5—arachidonate 5-lipoxygenase; PRNP—prion protein; RPS6KA3—ribosomal protein S6 kinase, 90 kDa, polypeptide 3; CDK1—cyclin-dependent kinase 1; KDM1A—lysine (K)-specific demethylase 1A; NR1H3—nuclear receptor subfamily 1, group H, member 3; MAPK9—mitogen-activated protein kinase 9; IL10—interleukin 10; BDNF—brain-derived neurotrophic factor; RGS6—regulator of G-protein signaling 6; S1PR2—Sphingosine 1-phosphate receptor 2; CCNB1—cyclin B1; CDK4—cyclin-dependent kinase 4; JUN—jun proto-oncogene; MTOR—mechanistic target of rapamycin; CDK6—cyclin-dependent kinase 6; SHC1—SHC transforming protein 1; GRB2—growth factor receptor-bound protein 2; RCOR1—REST corepressor 1; CCNA2—cyclin A2; STAT3—signal transducer and activator of transcription 3.
Node degree of Tiansi Liquid targets obtained through STITCH.
| Targets | Degree | Targets | Degree | Targets | Degree | Targets | Degree |
|---|---|---|---|---|---|---|---|
| Ribofuranoside | 1 | AKT1 | 33 | STAT3 | 29 | MAPK9 | 14 |
| Tyrosine | 5 | EGFR | 25 | COMT | 3 | IL10 | 15 |
| MIF | 6 | NOS3 | 23 | NPY1R | 3 | BDNF | 16 |
| MAPK1 | 23 | ACHE | 4 | PTGS2 | 16 | RGS6 | 3 |
| HMOX1 | 17 | IL8 | 21 | MCL1 | 15 | S1PR2 | 6 |
| PON2 | 1 | CASP3 | 17 | DHCR24 | 1 | CCNB1 | 16 |
| CCND1 | 22 | ADIPOQ | 8 | RUNX2 | 11 | CDK4 | 10 |
| CSN1S1 | 3 | NOS2 | 11 | ALOX5 | 6 | JUN | 33 |
| APOE | 22 | PRKCD | 11 | PRNP | 3 | MTOR | 24 |
| NR1H2 | 4 | NR1I2 | 3 | RPS6KA3 | 13 | CDK6 | 11 |
| PPARA | 22 | FDPS | 2 | CDK1 | 14 | SHC1 | 15 |
| UCP1 | 4 | MAPK8 | 26 | KDM1A | 2 | GRB2 | 16 |
| STK17B | 1 | CCNA2 | 6 | NR1H3 | 6 | RCOR1 | 1 |
Action view of functional targets of Tiansi Liquid obtained through STITCH. (•—Positive).
| Activation | Inhibition | Binding | Phenotype | Catalysis | Post-Trans. Mod. | Reaction | Expression | Score | |
|---|---|---|---|---|---|---|---|---|---|
| CCNB1 | • | • | • | • | • | 0.999 | |||
| CDK4 | • | • | • | • | • | • | 0.999 | ||
| JUN | • | • | • | • | • | • | 0.999 | ||
| MTOR | • | • | • | • | • | 0.999 | |||
| CDK6 | • | • | • | 0.999 | |||||
| SHC1 | • | • | • | • | • | 0.999 | |||
| GRB2 | • | • | • | • | 0.999 | ||||
| RCOR1 | 0.999 | ||||||||
| CCNA2 | • | • | • | • | • | 0.999 | |||
| STAT3 | • | • | • | • | 0.999 |
Retrieval of GO terms and their related genes via ClueGO.
| GO ID | GO Term | Term | Group | Associated Genes Found | Related Diseases |
|---|---|---|---|---|---|
| 46686 | Response to cadmium ion | 13.0 × 10−6 (770.0 × 10−6) | 13.0 × 10−6 (39.0 × 10−6) | [CDK1, HMOX1, MAPK9, PRNP] | Fibrosis, Hypertensive Disease, Inflammation, Diarrhea, Nervousness, Neoplasms, Lung Diseases, Hypoxia, Anoxia, Acidosis |
| 06636 | Unsaturated fatty acid biosynthetic process | 870.0 × 10−6 (4.3 × 10−3) | 900.0 × 10−6 (900.0 × 10−6) | [ALOX5, MIF, PTGS2] | Neoplasms, Hyperpigmentation, Nervousness, Agitation, Pituitary Diseases, Infective Disorder, Albinism, Tumor Angiogenesis, Hemorrhage, Hypertrophy, Diarrhea |
| 42982 | Amyloid precursor protein metabolic process | 100.0 × 10−6 (3.2 × 10−3) | 130.0 × 10−6 (260.0 × 10−6) | [ACHE, APOE, DHCR24] | Alzheimer’s disease |
| 19233 | Sensory perception of pain | 10.0 × 10−6 (660.0 × 10−6) | 1.1 × 10−6 (4.5 × 10−6) | [COMT, IL10, MAPK1, NPY1R, PTGS2] | Pain, Nervousness, Ulcer, Depressive disorder, Ulcer, Diabetes Mellitus, Neuralgia, Sensation Disorders, Anxiety, Disorders, Inflammation, Perceptual Disorders |
| 31348 | Negative regulation of defense response | 310.0 × 10−9 (27.0 × 10−6) | 25.0 × 10−12 (300.0 × 10−12) | [ADIPOQ, APOE, IL10, NR1H2, NR1H3, PPARA, PRKCD] | Dehydration, Dysequilibrium syndrome (balance disorder), Physiological stress |
| 32368 | Regulation of lipid transport | 460.0 × 10−12 (53.0 × 10−9) | 410.0 × 10−15 (6.2 × 10−12) | [ADIPOQ, AKT1, APOE, MIF, NR1H2, NR1H3, PPARA, PRKCD] | Alzheimer’s disease, Motor neuron disease, Sphingolipidoses, Nervousness, Nervous system disorder, Hereditary Motor, Neurone Disease, Depression |
| 10888 | Negative regulation of lipid storage | 200.0 × 10−9 (19.0 × 10−6) | 20.0 × 10−12 (260.0 × 10−12) | [NR1H2, NR1H3, PPARA, TNF] | Obesity, Diabetes Mellitus, Pituitary Diseases |
| 32722 | Positive regulation of chemokine production | 17.0 × 10−6 (960.0 × 10−6) | 20.0 × 10−12 (260.0 × 10−12) | [ADIPOQ, HMOX1, MIF, TNF] | Cholangiocarcinoma, Inflammatory Response, Arthritis, Rheumatism, Bacterial Infections |
| 50880 | Regulation of blood vessel size | 210.0 × 10−9 (19.0 × 10−6) | 9.2 × 10−12 (120.0 × 10−12) | [AKT1, APOE, EGFR, HMOX1, NOS2, NOS3, PTGS2] | Retinal Degeneration, Albinism |
| 33002 | Muscle cell proliferation | 1.0 × 10−9 (110.0 × 10−9) | 35.0 × 10−12 (380.0 × 10−12) | [ADIPOQ, AKT1, CDK1, COMT, EGFR, HMOX1, IL10, PTGS2, TNF] | Atherosclerosis, Hyperplasia, Vascular Diseases, Cardiovascular Diseases, Inflammation, Stenosis, Dental Plaque |
| 32496 | Response to lipopolysaccharide | 200.0 × 10−15 (25.0 × 10−15) | 5.5 × 10−15 (88.0 × 10−15) | [AKT1, CASP3, COMT, CXCL8, IL10, MAPK1, MAPK8, MIF, NOS2, NOS3, NR1H3, PTGS2, RPS6KA3, TNF] | Inflammation, Systemic Infection, Innate Immune Response, Neoplasms, Decreased Immunologic Activity, Septic Shock, Atherosclerosis, Lung Injury, Autoimmune Reaction, Nervousness |
| 71219 | Cellular response to molecule of bacterial origin | 37.0 × 10−12 (4.4 × 10−9) | 5.5 × 10−15 (88.0 × 10−15) | [AKT1, CXCL8, IL10, MAPK1, MAPK8, MIF, NOS2, NOS3, NR1H3, TNF] | Septic Shock, Innate Immune Response, Communicable , Diseases |
| 51100 | Negative regulation of binding | 120.0 × 10−9 (11.0 × 10−6) | 9.7 × 10−18 (160.0 × 10−18) | [ADIPOQ, HMOX1, IL10, KDM1A, MAPK8, PPARA, PRKCD] | Tissue Adhesions, Inflammation, Escherichia Coli Infections, Edema, Neoplasms, Hemorrhage, Basophilic Leukemia, Dwarfism, Pertussis, Nervousness, Headache, Hyperglycemia, Pituitary Diseases, Mammary Neoplasms, Diabetes Mellitus, Kidney Diseases, Obesity, Diabetes Mellitus, Hiv Infections, Neoplasms, Leukemia |
| 2000377 | Regulation of reactive oxygen species metabolic process | 380.0 × 10−9 (33.0 × 10−6) | 9.7 × 10−18 (160.0 × 10−18) | [AKT1, EGFR, IL10, PRKCD, PTGS2, TNF, UCP1] | Neoplasm metastasis, Neoplasms, Cancer of nasopharynx, Carcinoma |
| 32091 | Negative regulation of protein binding | 120.0 × 10−9 (12.0 × 10−6) | 9.7 × 10−18 (160.0 × 10−18) | [ADIPOQ, IL10, KDM1A, MAPK8, PPARA, PRKCD] | Flushing, Tuberculosis |
| 31663 | Lipopolysaccharide-mediated signaling pathway | 620.0 × 10−9 (52.0 × 10−6) | 9.7 × 10−18 (160.0 × 10−18) | [AKT1, MAPK1, MIF, NOS3, TNF] | Ischemia, Neoplasms, Hepatic ischaemia, Fibrosis, Brain Injuries, Depressive Disorder, Cystic Fibrosis, Neurodegenerative Disorders, Anoxia, Neuroblastoma, Alzheimer’s Disease |
| 45923 | Positive regulation of fatty acid metabolic process | 31.0 × 10−9 (3.2 × 10−6) | 9.7 × 10−18 (160.0 × 10−18) | [ADIPOQ, NR1H2, NR1H3, PPARA, PTGS2] | Obesity, Diabetes Mellitus, Ischemia, Neoplasms, Inflammation |
| Tumor Angiogenesis, Fatty Liver, Hyperthyroidism |
Corrected with Bonferroni step down.
Figure 4Retrieval of functionally grouped networks for the candidate targets of Tiansi Liquid, obtained via ClueGO, with terms as nodes associated. Each group is represented by only the label of the most significant term. The node size indicates the term enrichment significance. Functionally associated groups partially overlap.
Figure 5Mechanistic effect of Tiansi Liquid against depression.